Skip to content
MARKETS / NASDAQ / UFPT
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

UFP Technologies Inc. UFPT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$602.8M
▲ 19.5% YoY
$68.3M
▲ 15.8% YoY
$91.9M
▲ 45.0% YoY
In brief

What this company does

The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. Its single-use and single-patient devices and components are used in medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. The Company has nineteen manufacturing locations that are ISO 13485 certified and thirteen that are FDA registered. As of January 24, 2026, the Company had a total of 4,846 full-time employees and 503 temporary workers. For the year ended December 31, 2025, two customers accounted for approximately 24.3% and 21.5% of the Company's net sales, respectively. The Company was incorporated in the State of Delaware in 1993.

Written from the business description in UFP TECHNOLOGIES INC's annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 602.8M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 602.8 · Net income 68.3
250.0M500.0M200920112013201520172019202120232025
Compound annual growth
+19.4%
+27.4%
+15.8%
+11.3%
+17.8%
+38.6%
+24.6%
+17.1%
+37.7%
+23.6%
+13.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +27.4% a year over five years — but profit grew faster: net income at +38.6%, earnings per share at +37.7%.

The share count rose from 0.01B to 0.01B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
11 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 15.3% · Net 11.3%
5%10%15%200920112013201520172019202120232025
ROE
FY2025 · ROE 17.8%
5%10%15%200920112013201520172019202120232025

Each USD of equity produced 18 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 91.9
40M80M200920112013201520172019202120232025
Net buybacks $ Dividends $
FY2015 · Dividends — · Net buybacks 587000.0
2000004000002015

Total assetsUSD 655.1M
EquityUSD 423.9M
CashUSD 20.3M
Gross debtUSD 135.5M
Net debtUSD 115.2M
Current ratio2.68×

Net debt stands at 27% of equity.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.60.50.40.40.20.20.20.20.10.10.10.10.10.10.10.10.1
Operating income $B0.10.10.10.10.00.00.00.00.00.00.00.00.00.00.00.00.0
EBITDA $B0.10.10.10.10.00.00.00.00.00.00.00.00.00.00.00.00.0
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.10.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Free cash flow $B0.10.10.00.00.00.00.00.00.00.0−0.0−0.00.00.00.00.00.0
EPS, diluted $8.757.585.835.452.091.772.631.931.261.101.051.051.591.551.481.370.94
Dividend / sh $·················
Payout %·················
ROE %17.818.817.219.38.67.913.110.87.87.47.68.414.216.219.418.9·
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image